# OnCo record nct06623422 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06623422/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06623422", "NCT06623422" ;
  schema:name "A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)"@en ;
  schema:alternateName "INTerpath-009"@en ;
  schema:description "A phase 3 trial of Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine and Intismeran autogene in non-small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06623422/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06623422> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2024-10-21" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/resectable-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/neoantigen-mrna-vaccine/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/intismeran-autogene/> ;
  onco:companies <https://onco.cc/companies/merck/> .